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INTRODUCTION
Tr e a t m e n t  t a r g e t s  i n 
Inflammatory Bowel Disease 
(IBD) have shifted over the 
recent  years .  Therapeut ic 
strategies focusing on induction 
and maintenance of clinical 
remission have no effect on the 
natural course of the disease [1, 
2]. In the late 1990s, the advent of 
biologic agents for the treatment 
of IBD has taught us that while 
patients may be in clinical 
remission, they may still have 
ongoing mucosal inflammation 
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ABSTRACT
Background & Aims: Recently, treatment goals in inflammatory bowel disease (IBD) in clinical trials have 
shifted from mainly symptom-based to more mucosa-driven. Real world data on treatment priorities are 
lacking. We aimed to investigate the current practice and most commonly used definitions of IBD treatment 
targets among Dutch gastroenterologists.
Methods: Dutch gastroenterologists were asked to participate in a computer-based nation-wide survey. We 
asked questions on demographics, opinion and current practice regarding IBD treatment targets. 
Results: Twenty-four percent (134/556) of the respondents completed the survey. For both Crohn’s disease 
(CD) (47.3%, 61/129) and ulcerative colitis (UC)(45%, 58/129) the main treatment goal was to achieve and 
maintain deep remission, defined as clinical, biochemical and endoscopic remission. Seventy-six percent 
of the participants use mucosal healing (MH) as a potential treatment target for IBD, whereas 22.6% use 
histological remission. There is no single definition for MH in IBD. The majority use Mayo score ≤ 1 in UC 
(52%) and ‘macroscopic normal mucosa’ in CD (66%). 
Conclusion: More stringent and mucosa-driven treatment targets as ‘deep remission’ and ‘mucosal healing’ 
have found traction in clinical practice. The most commonly used definition for MH in routine practice is 
endoscopic MAYO score ≤ 1 in UC and ‘macroscopic normal mucosa’ in CD.
Key words: Inflammatory bowel disease – mucosal healing – treatment goals – deep remission – ulcerative 
colitis – Crohn‘s disease. 
Abbreviations: CD: Crohn’s disease; CDEIS: Crohn‘s Disease Endoscopic Index of Severity; IBD: Inflammatory 
Bowel Disease; IBDU: IBD unclassified; IOIBD: International Organization for the Study of Inflammatory 
Bowel Diseases; MH: Mucosal healing; MMH: Microscopic mucosal healing; PROMS: Patient reported 
outcome measures; SES-CD: Simple endoscopic score for Crohn’s disease; UC: ulcerative colitis; UCEIS: 
Ulcerative Colitis Endoscopic Index of Severity.
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resulting in structural damage [3-8]. This has led to the concept 
of mucosal healing (MH) as a more meaningful therapeutic 
target in clinical practice. Indeed, emerging data suggest that 
MH is strongly associated with a reduction in steroid use, 
complications, hospitalizations, and surgeries. This has fueled a 
shift in IBD trials and guidelines from mainly symptom-based 
management of IBD patients to more complex management 
considerations. Composite treatment targets including both 
patient reported outcome measures (PROMS) and mucosal 
healing are promoted [9-15, 34]. Despite the clinical relevance 
of MH, no standardized definition is available yet. In addition, 
definitions for newly defined, but not yet widely accepted 
targets, such as “deep remission” or “histological remission” are 
emerging in clinical trials. There are a number of endoscopic 
disease activity scores that assist endoscopists, but few have 
been properly evaluated and validated in large cohorts. 
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Good examples are the Ulcerative Colitis Endoscopic Index 
of Severity (UCEIS) for ulcerative colitis (UC) [16, 17], the 
Crohn‘s Disease Endoscopic Index of Severity (CDEIS) and the 
Simple Endoscopic Score (SES-CD) for Crohn’s disease (CD)
[18-20]. Practical and commonly used definitions for MH such 
as “the complete resolution of the visible alteration or lesions” 
[21], or endoscopic Mayo score ≤ 1 [22] have the disadvantage 
of higher interobserver variability and limited accuracy [9, 
23, 24]. In view of the above, (inter)national guidelines are 
still unclear which treatment goals we should use in routine 
clinical practice, and how much efforts, risks and resources we 
should use to achieve implementation [25-28]. This leads to 
the question how endoscopic endpoints such as MH are used 
in real world IBD practices. 
Therefore, we conducted a survey to investigate the current 
practice and used definitions of IBD treatment targets among 
Dutch gastroenterologists. In addition, we aimed to map factors 
that influence decision-making in clinical practice. 
METHODS
Survey development, testing and distribution
We developed a structured survey on IBD management 
in daily practice consisting of 23 multiple-choice questions 
(Q1-23) including 3 clinical cases and 3 endoscopy images 
(Supplementary Appendix). The cases and images were mainly 
designed to monitor the internal consistency of the survey. 
Academic review of important literature and guidelines on 
this topic, as well as gastroenterologist’s interviews guided 
the survey development. The survey was published at the 
professional survey website www.surveymonkey.com between 
June 2015 and October 2015. In accordance with survey design 
guidelines [29], a pilot questionnaire was pre-tested on 5 
dedicated IBD gastroenterologists to examine for questionnaire 
applicability, clarity, and content validity. As a result of this 
pilot survey, the initial questionnaire was modified. The 
questionnaire was shortened, questions asked on treatment 
targets were made more clear and specific, ‘other’ response 
options were included, and the clinical cases were refined. The 
questionnaire (Supplementary Appendix) led to collection of 
data on demographics of participants and their institutes (7 
questions), their opinion and current clinical practice with 
respect to IBD treatment targets (13 questions, of which 3 
contained endoscopy images) and the most relevant decision-
making factors in their clinical IBD practice (3 cases). With 
respect to IBD treatment targets, we asked both general and 
more detailed questions. To ensure that participants should 
only answer for those relevant survey questions, we redirected 
those that answered negatively on general questions in a specific 
topic to the next cluster of questions on the subsequent topic.
Participants
The survey and two reminders were distributed to potential 
participants through e-mail. A cover e-mail explained the 
purpose of the survey and provided a link to the survey. 
Responses were accepted up to 4 months from the initial 
survey distribution date. Participants comprised all Dutch 
gastroenterologists and gastroenterology (GI) fellows, who 
were members of the Dutch association for gastroenterologists. 
As the survey was based on voluntary participation and 
information disclosure, the study protocol did not need to 
undergo a formal review by an Ethics Committee. Voluntary 
survey return was taken as consent. 
Data collection and statistics
Data collection was anonymous and treated confidentially. 
Statistical analyses were performed using descriptive 
statistics, independent t-tests, and nonparametric tests. 
We used descriptive statistics to analyze the results using 
counts and proportions for categorical data and means and 
standard deviations for continuous variables. Missing values 
were not imputed. The answers to most questions regarding 
definition, treatment goals and the case descriptions were 
tested against the mean number of years of experience (t-test 
after dichotomization) and type of hospital (chi-square). We 
assumed a two-tailed p < 0.05 as statistically significant. We 
examined the consistency of the participants’ answers by testing 
associations between theoretical questions and clinical cases or 
endoscopy images concerning the same subject (chi-square). 
Interobserver agreement for endoscopy images was tested by 
kappa statistics. Statistical analysis was performed with IBM 
SPSS version 22, excel version 2007, and GraphPad Prism 
(GraphPad Software,version 5.03).
RESULTS
Participants
The survey was sent to 556 eligible e-mail addresses. 
Overall, 134 physicians participated and completed the survey 
(24%). The response rate was 25% for gastroenterologists 
(n=97/396) and 23% for GI fellows (n=37/160). Table I contains 
the demographic characteristics of the participants and their 
working environment. Fifty-nine percent of the participants 
were male (79/134), mean age was 42.1 years and the mean 
duration of working experience as a gastroenterologist was 
8.5 years (fellows reported 0 on this question). 
Table I. Demographic characteristics of the participants
Variable n/N(%)
Response rate GI fellows 37/160 (23%)
Response rate gastroenterologists 97/396 (25%)
Male sex 79/134 (59%)
Age (years) (mean ± SD) 42.1 ± 9.8 (range 28-65)
Type of hospital
University hospital 44/134 (33%)
Teaching hospital 59/134 (44%)
General hospital 31/134 (23%)
IBD population#
<400 10/134 (8%)
400-800 44/134 (33%)
800-1200 38/134 (28%)
>1200 42/134 (31%)
Treat IBD in practice 130/134 (97%)
IBD = inflammatory bowel disease; # total number of IBD patients in follow 
up at the outpatient clinic of the center
Treatment targets in IBD 467
J Gastrointestin Liver Dis, December 2016 Vol. 25 No 4: 465-471
Survey topics
Treatment goals (Q8-9)
All selectable treatment goals, and their range are depicted 
in Fig. 1. The main overall treatment goal was to achieve and 
maintain deep remission for both CD (47.3%, 61/129) and 
UC (45%, 58/129). In this survey, this was defined as clinical, 
biochemical and endoscopic remission. Participants who 
indicated deep remission as a key treatment goal (N=61 in 
CD, N= 58 in UC), had fewer years of working experience. 
This was significant for CD (11.5 ± 9.8 vs 6.0 ± 7.3 years ; p= 
0.001); for UC the same trend was seen, but this did not reach 
the threshold for statistical significance (10.2 ± 9.5 versus 7.2 ± 
8.5 years; p= 0.06). We found no association between treatment 
goals and the type of hospital (Table II). 
Mucosal healing and definitions (Q10-13)
Seventy-six percent (98/129) of the participants indicated 
that they used MH as a potential treatment target for IBD. Years 
of working experience or type of hospital were independent 
of the use of MH (Table II). Ninety-four participants (73%) 
answered more detailed questions on MH. The majority (70%; 
66/94) mentioned that they used MH as endpoints for both 
CD, IBD unclassified (IBDU) and UC. 
To define MH in UC, 52% (49/94) used the Mayo score, 
with 40% (38/94) using ‘macroscopic normal mucosa’ as a 
definition for MH (Fig. 2a). For UC, we did not detect an 
association with the type of definition used for MH and years 
of working experience (Table II). The majority of respondents 
(66%; 62/94) used ‘macroscopic normal mucosa’ to define MH 
in CD, with almost one-fifth (18.1%; 17/94) using the CDEIS, 
and 9.6% (9/94) the SES-CD (Fig. 2b). Again, we found no 
association with the type of definition used for MH and years 
of working experience, but in university hospitals the MH 
definition ‘macroscopic normal mucosa’ was used significantly 
more often (p=0.043)(Table II). 
Histological remission (microscopic mucosal healing) and 
deep remission (Q14-Q17)
Histological remission (microscopic mucosal healing, 
MMH) as a possible treatment target for IBD was used by 
22.6% (28/124) of the participants. Twenty-seven participants 
(22%) provided additional details on MMH. Fifty-nine percent 
(16/27) stated to use MMH for CD, as well as for IBDU and 
UC, with 22.2% (6/27) using it only in UC. The most frequently 
used definition of MMH was ‘perfectly normal mucosa’ 
(44.4%; 12/27). This was followed by the criteria of Truelove 
and Richards (29.6%; 8/27) (Fig. 2c). There was no association 
between the used definition of MMH and years of working 
experience or type of hospital (Table II).
The participants defined deep remission frequently as 
‘clinical, biochemical and endoscopic remission’ (56.5%; 
70/124), with the definition ‘clinical, biochemical, endoscopic 
and histological remission’ (39.5%; 49/124) following suit (Fig. 
2d). There was no association between the latter (most stringent 
definition of deep remission) and years of working experience 
or type of hospital (Table II). 
Endoscopy images (Q18-20)
One hundred and twenty-four participants (93%) assessed 
3 endoscopy images of the colonic mucosa on MH, to monitor 
for internal consistency of the survey. The 3 images linked 
to circle diagrams indicating the opinion of the participants 
on MH are depicted in Supplementary Fig. 3a-c. The inter 
Fig. 1. Selectable treatment targets in ulcerative colitis (1a) and Crohn’s disease (1b) 
(*Defined as normal laboratory results and normal fecal calprotectine; **Defined as 
clinical, biochemical and endoscopic remission; MH = mucosal healing; UC= ulcerative 
colitis; CD = Crohn’s disease; GE= gastroenterologist).
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observer agreement depicted as Fleiss generalized kappa was 
almost perfect for respectively image A (0.94) and image B 
(0.88) and moderate for image C (0.53). To control for internal 
consistency, we compared answers of Q12 (‘which definition 
do you use for mucosal healing?’) with the judgment of the 
endoscopic image C. For this purpose we created two groups: 
1) MH defined as Mayo score 0 (answer Q12b); 2) MH defined 
as Mayo score ≤ 1 (answer Q12c). Some 68% (43/63) of the 
participants in group 1 judged image C as MH, while 48% 
(10/21) did from group 2 (p=0.09).
Clinical cases (Q21-23)
The survey comprised three clinical cases (Q21-23). The 
first 2 cases (Q21-22) dealt with the use of deep remission 
in UC patients (Supplementary Fig. 4a-b), and were used to 
test internal consistency of the survey. Question 8 (Q8) is 
Table II. Survey answers tested against working experience and type of hospital
Question (Q) N Workinga 
Experience
P Type of hospital P
University Teaching General 
Q8 Treatment goal UC deep remission 58 10.3±9.5 0.06 21 (36%) 20(48%) 17(61%)
0.08Q8 Treatment goal UC other answers 71 7.22±8.5 38 (64%) 22(52%) 11(39%)
Q9 Treatment goal CD deep remission 61 6.0±7.3 0.001 25(42%) 21(50%) 15(54%)
0.57Q9 Treatment goal CD other answers 68 11.5±9.8 34(58%) 21(50%) 13(46%)
Q10 MH used as treatment goal - yes 98 8.6±9.0 0.57 49(83%) 31(74%) 18(64%)
0.15Q10 MH used as treatment goal - no 31 9.7±9.6 10(17%) 11(26%) 10(36%)
Q12 Definition MH in UC- macr.normal 38 10.6±9.7 0.31 24(50%) 9(30%) 5(31%)
0.08Q12 Definition MH in UC- Mayo 50 7.8±8.8 22(46%) 20(67%) 8(50%)
Q12 Definition MH in UC- other 6 7.0±5.8 2(4%) 1(3%) 3(19%)
Q13 Definition MH in CD- macr.normal 63 9.5±8.9 0.34 37(77%) 19(63%) 7(44%)
0.04bQ13 Definition MH in CD- other 31 7.6±9.4 11(23%) 11(37%) 9(56%)
Q14 Stringent definition deep remission 49 9.0±8.9 0.92 24(42%) 16(39%) 9(35%)
0.81Q14 Other definition deep remission- 75 9.2±9.4 33(58%) 25(61%) 17(65%)
Q15 MMH used as treatment goal –yes- 28 11.5±8.1 0.12 14(25%) 9(22%) 5(19%)
0.86Q15 MMH used as treatment goal –no- 96 8.5±9.4 43(75%) 32(78%) 21(81%)
ayears; mean ± SD; bP 0.013 University hospital versus General; MH = mucosal healing; UC= ulcerative colitis; CD = Crohn’s 
disease; MMH= histological remission.
Fig. 2. Definitions used for mucosal healing in ulcerative colitis (2a), in Crohn’s disease (2b), for histological 
remission (2c) and for deep remission in inflammatory bowel disease (2d). (MH = mucosal healing; UC= ulcerative 
colitis; CD = Crohn’s disease; MMH= histological remission)
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the theoretical part that complements these 2 cases (‘what 
do you consider the most important treatment target in your 
patients with UC’) and therefore we analyzed the internal 
consistency of the participants by comparing the answers of Q8 
and Q21/22 (n=120). For both cases and Q8, we created two 
groups of respondents: 1) treatment target is deep remission 
(answer Q8e) versus 2) all other answers (answer Q8a-d). Most 
respondents chose to intensify their treatment in both cases 
(Q21: 75%; 92/124 /Q22: 84%; 103/123 ), with a significant 
association with the answer ‘deep remission’ in Q8 for both 
Q21 (p=0.026) and Q22 (p=0.03). The third case (Q23) dealt 
with ‘stopping criteria’ for IBD medication after one year of 
deep remission in UC, an issue that is outside the scope of 
this article. Fifty-three percent (65/122) of the participants 
were willing to stop the immunosuppressive medication in a 
young male patient, who was in deep remission for 1.5 years, 
but was initially treated top-down because of severe pancolitis 
at presentation.  
DISCUSSION
This nationwide survey was designed to determine the 
current practice of IBD treatment targets among Dutch 
gastroenterologists and to assess factors that influence decision 
making. Almost half of all respondents use deep remission as 
a key treatment goal. Deep remission was mostly defined as 
‘clinical, biochemical and endoscopic remission’. The majority 
are willing to intensify treatment to reach deep remission. Over 
three-quarters of the gastroenterologists use MH as a potential 
treatment target for IBD, whereas less than a quarter use 
histological remission. There is no single definition for MH in 
IBD. The majority use Mayo score ≤ 1 in UC and ‘macroscopic 
normal mucosa’ in CD. 
Nowadays, MH is an accepted treatment target in clinical 
IBD trials [9, 15, 21] and has  been accepted in the guidelines 
[25-28]. We found that 75% of the gastroenterologists use 
MH in daily IBD practice, irrespective of experience or 
type of hospital. Our data suggest that the concept of MH is 
embraced by many IBD practices. This indicates a watershed 
with the situation in 2010 when a Swiss survey found that 
gastroenterologists judged clinical activity as more relevant 
than endoscopic severity or biomarkers [30]. Worth noting, 
and probably partly explaining the discrepancy, is that the 
Swiss participants were all gastroenterologists, with on average, 
a longer working experience, with probably less IBD patients 
in their center. However, it remains important to realise that 
we cannot achieve MH in all IBD patients with the currently 
available therapies. In UC, varying data on achieving MH with 
the use of 5-ASA (36,9%-80%)[31, 32], azathioprine (53%)
[33] and biologics 32%-62% [34-37] exist, depending on the 
used definition of MH and duration of follow up. In the case 
of CD similar results for budesonide (24%)[38], azathioprine 
(16.5-73%)[38-40], combinations of azathioprine and biologics 
(43,9-70.4%) [39, 40], and biologics (20%-63%) [39-42] exist. 
Newly defined treatment targets, such as deep or 
histological remission come from endpoints defined for clinical 
IBD trials [40, 43-44], but are not widely accepted or integrated 
in the IBD guidelines [25-28]. Surprisingly, almost half of all 
respondents used deep remission as a key treatment target in 
daily clinical practice, which suggests that practice is being 
shaped prior to development or revision of guidelines. Most 
guidelines date from around 2011 and are updated every 3 
years [25-27]. Indeed, a recent consensus meeting initiated by 
the International Organization for the Study of Inflammatory 
Bowel Diseases (IOIBD) did define composite treatment targets 
for both UC and CD, combining both clinical and endoscopic 
remission [45]. Also, the majority of these respondents have 
fewer years of working experience. Possibly, a greater focus on 
evolving treatment targets in the current training schemes of 
GI fellows plays a role here. Histological remission appears to 
be used less often in daily practice, with a preference for UC 
when used. This is in line with international guidelines that do 
not advise histological remission as a treatment target [25-27]. 
Also, IOIBD experts agreed upon histological remission as an 
adjunctive goal that might come into view in the future, in 
particular in UC [45]. A unified single definition for MH in IBD 
is lacking. For UC, several endoscopic scoring systems have 
been developed but none were validated until recently [46-47]. 
In 2012, the UCEIS has been developed and validated [16, 17]. 
UCEIS is rather complex and time consuming, which makes it 
less attractive for routine use in daily practice [48]. Currently, 
the IOIBD consensus group recommends the endoscopic Mayo 
score in UC because of its ease of use and established predictive 
value [45,49-50]. In line with this recommendation we found 
that more than half of the participants use the Mayo score (0 
or ≤ 1) to define MH in UC. Of these, one-third defined MH 
as Mayo score 0. In the literature, the debate continues whether 
Mayo score 0 or 1 qualifies as a definition for MH [45, 51]. 
Still, in UC 40% of the participants indicated the definition 
of MH as ‘macroscopic normal mucosa’, and the same applied 
for 66% in CD. The latter is in accordance with the IOIBD 
consensus  which agreed on the ‘absence of ulceration’ as an 
endoscopic target in CD [45]. Both CDEIS and SES-CD are 
validated scoring systems for CD. Surprisingly, we found that 
only one-fifth use the CDEIS, and 9.6% the SES-CD, while the 
CDEIS is known as time consuming and complex [19, 20, 48]. 
The participants went through three clinical UC cases 
dealing with treatment targets and stopping criteria of 
immunosuppressive medication. In line with their answers on 
the theoretical questions concerning treatment targets in UC, 
most respondents chose to intensify the treatment to reach 
deep remission. 
Our study has several strengths and some limitations. 
Mucosal healing has been a theme in clinical trial design but 
it was unknown whether this concept had been adopted in 
clinical practice. Our data suggest that it has. Secondly, this 
survey has been developed according to survey guidelines 
[29], and carried high internal consistency when comparing 
theoretical questions with practical cases. Naturally, the 
voluntary participation to this survey creates response bias. 
Since our target population was ‘gastroenterologists who 
treat IBD patients’, we chose a purposive sampling design and 
mentioned this element in the cover e-mail that was sent to 
possible participants. 
The purposive sampling, national design of our survey, and 
the inclusion of physicians from both general and academic 
hospitals, were in support of the external generalizability of 
our findings. 
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CONCLUSION
We demonstrated that the use of MH, as a marker of 
treatment efficacy for both UC and CD, has made its way into 
routine practice. Although there is no single definition for 
MH, the majority of gastroenterologists use endoscopic MAYO 
score ≤ 1 in UC or ‘macroscopic normal mucosa’ in CD. This 
seems to be the least complex and most pragmatic definition 
for widespread use in clinical practice. 
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Fig. 3a-c. Endoscopy images and % participants judging the image as mucosal healing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Treatment targets and treatment options used to achieve treatment goals in case 1 (4a) and 
case 2 (4b) 
Supplementary Appendix : Survey 
 
1.  Which gender do you have? 
A.  Male 
B.  Female 
2.  What is your age? 
3.  What is your profession? 
A.  Gastroenterologist 
 B.  GI Fellow  
  C.  Internist 
 D.  Internal medicine fellow 
  E.  Other (give explanation) 
4.  How many years have you been medical specialist? (If fellow fill in 0) 
  .. years 
5.  In what type of hospital do you work? 
 A.  University hospital 
  B.  Teaching hospital 
  C.  General hospital 
 D.  Other (give explanation) 
6.  How many IBD outpatients are treated in your center? 
 A.  <400 patients 
  B.  400‐800 patients 
  C.  800‐1200 patients 
 D.  >1200 patients 
7.  Do you treat IBD patients in clinical practice? 
 A.  Yes 
  B.  No 
8.  What is your most important treatment goal in UC patients?  
 A.  Induce and maintain a good quality of life 
  B.  Induce and maintain clinical remission 
  C.  Induce and maintain biochemical remission (normal laboratory results  and feces calprotectine) 
 D.  Induce and maintain endoscopic remission (MH) 
  E.  Induce and maintain deep remission (combination of B, C and D) 
9.  What is your most important treatment goal  in CD patients?  
 A.  Induce and maintain a good quality of life 
  B.  Induce and maintain clinical remission 
  C.  Induce and maintain biochemical remission (normal laboratory results and feces calprotectine) 
 D.  Induce and maintain endoscopic remission (MH) 
  E.  Induce and maintain deep remission (combination of B, C and D) 
10.  Do you ever use endoscopic remission (MH) as a treatment target in your IBD patients? 
 A.  Yes 
  B.  No 
11.  In which patients  do you use endoscopic remission (MH) as a treatment target? 
 A.  CD 
 B.  UC 
 C.   IBD‐U 
 D.  Answer A and B 
 E.  Answer A and C 
 F.  Answer B and C 
 G.   All of the above answers 
12.  Which definition do you use for endoscopic remission (MH) in UC patients? 
 A.  Macroscopic complete normal mucosa 
B.  Mayo endoscopy score 0 
C.  Mayo endoscopy score ≤ 1 
D.  ‘D Haens scoreA
  E.  UCEISB score 0 
  F.  UCEISB score < 4 
 G.  Other (give explanation) 
13.  Which definition do you use for endoscopic remission (MH) in CD patients?  
 A.  Macroscopic complete normal mucosa 
  B.  CDEISC score 0 
  C.  CDEISC score < 4 
 D.  SES‐CDD
  E.  Other (give explanation) 
14.  How do you define deep remission in your IBD patients? 
 A.  Clinical remission 
  B.  Clinical and biochemical remission 
  C.  Clinical, biochemical and endoscopic remission 
 D.   Clinical, biochemical endoscopic and histological remission 
15.  Do you ever use histological remission/microscopic mucosal healing (MMH) as a treatment 
target in your IBD patients? 
 A.  Yes 
  B.  No 
16.  In which patient group do you use MMH as a treatment target? 
 A.  CD 
  B.  UC 
  C.   IBD‐U 
 D.  Answer A and B 
  E.  Answer A and C 
  F.  Answer B and C 
 G.   All of the above answers 
17.  Which definition for MMH do you use? 
 A.  Truelove and RichardsE
 B.  Perfectly normal mucosa 
 C.  Riley criteriaF
D.  Geboes scoreG
 E.  Other (give explanation) 
18.  Do you think this image shows endoscopic remission? 
 A.  Yes 
 B.  No 
19.  Do you think this image shows endoscopic remission? 
A.  Yes 
 B.  No 
20.  Do you think this image shows endoscopic remission? 
A.  Yes 
B.  No 
21.  (1/3) Case: 45 year old female; pancolitis ulcerosa since 1994, is on 2 grams mesalazine/day 
maintenance dose; no symptoms, normal laboratory results, feces calprotectine 200µg/g. At 
surveillance colonoscopy:  sigmoiditis MAYO I. What is your treatment?  
A.  Maintain 5‐ASA dose (patient is in  clinical and biochemical remission) 
B.  Increase 5‐ASA dose to achieve deep remission 
C.  Add topical medication to oral 5‐ASA to achieve deep remission 
D.  Combination of B. and C. to achieve deep remission 
E.  Add an immunomodulator to achieve deep remission 
22.  (2/3) Case: 22 year old male, pancolitis ulcerosa since 2011; Severe disease course at 
presentation: top down treatment with infliximab 5mg/kg induction scheme followed by 
maintenance therapy 1x/8 weeks combined with 6‐mercaptopurine. Now: no symptoms,   
laboratory results: CRP 10, feces calprotectine 250 µg/g and at colonoscopy rectosigmoiditis 
MAYO II. What is your treatment? 
A.  Maintain current medication (patient is in  clinical remission) 
 B.  Maintain current medication (patient is in clinical and biochemical remission) 
 C.  Add topical medication to current medication to achieve deep remission 
D.  Intensify/switch current immunomodulators (after control levels) to achieve deep remission 
E.  Combination of C. and D.  
23.   (3/3) Case: 22 year old male, pancolitis ulcerosa since 2011; Severe disease course at 
presentation: top down treatment with infliximab 5mg/kg induction scheme followed by 
maintainance therapy 1x/8 weeks combined with 6‐mercaptopurine. Since 1,5 years no 
symptoms, laboratory results: normal, CRP<5, feces calprotectine 250µg/g and normal mucosa  
at colonoscopy What is your treatment? 
A.  Maintain current medication because of  to “prognostic poor” ulcerative colitis 
B.  Stop anti‐TNF therapy because of >1 year clinical, biochemical and endoscopic remission 
C.  Stop 6‐mercaptopurine because of >1 year clinical, biochemical and endoscopic remission 
A 'D Haens score = normaal ogende mucosa zonder: 1) toegenomen kwetsbaarheid, 2) bloedingen, 3) erosies, 4) zweren.   
  (‘D Haens score = normal‐looking mucosa without: 1) increased vulnerability, 2) haemorrhages, 3) erosions, 4)ulcers) 
B UCEIS = Ulcerative Colitis Endoscopy Index of Severity 
C CDEIS = Crohn's Disease Endoscopy Index of Severity 
D SES‐CD = Simple Endoscopic Score for Crohn's Disease 
E Truelove and Richards: graad 1: geen significante ontsteking, graad 2: mild‐gemiddelde ontsteking, graad 3: ernstige ontsteking  
(Truelove and Richards: grade 1: no significant inflammation, grade 2: mild‐moderate inflammation, grade 3: severe inflammation) 
F Riley: score van 6 kenmerken: acuut ontstekingsinfiltraat, crypt abcessen, mucus depletie, epitheliale integriteit, chronisch inflammatoir infiltraat, 
abnormaliteiten in crypte architectuur 
( Riley: score of 6 features: acute inflammatory cell infiltrate, crypt abscesses, mucine depletion, surface epithelial integrity, chronic inflammatory 
cell infiltrate, crypt architectural irregularities)  
G  Geboes: score van 6 kenmerken: architecturele veranderingen, chronisch inflammatoir infiltraat, neutrofielen en eosinofielen in lamina propria, 
neutrofielen in epitheel, crypt destructie, erosie of ulceratie. 
  (Geboes: score of 6 features: architectural changes, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in 
epithelium, crypt destruction, erosion or ulceration). 
 
 
 
 
 
 
 
 
 
 
 
